Table 3.
BFR |
HST |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 0 |
Week 12 |
Week 0 |
Week 12 |
|||||||||
PRE | POST 1 min | POST 30 min | PRE | POST 1 min | POST 30 min | PRE | POST 1 min | POST 30 min | PRE | POST 1 min | POST 30 min | |
s-SHBG, nmol/l | 117 ± 107 | 117 ± 96 | 112 ± 90 | 110 ± 90 | 119 ± 96* | 112 ± 99 | 111 ± 78 | 106 ± 71 | 107 ± 77 | 108 ± 87 | 113 ± 93 | 107 ± 94 |
s-AND, nmol/l | 10.7 ± 4.8 | 11.5 ± 7.3 | 12.2 ± 8.5 | 10.4 ± 4.8 | 11.2 ± 7.0 | 11.0 ± 5.7 | 13.4 ± 7.8 | 14.2 ± 9.6 | 12.6 ± 9.7 | 11.1 ± 6.4 | 12.7 ± 5.7 | 11.2 ± 7.9 |
Values are expressed as means ± SD. Each individual performed each of the two training protocols in a contralateral manner, with singular sessions of HST and BFR being performed both before (week 0; n = 7) and after (week 12; n = 9) 12 weeks of HST and BFR, in each case on different days, separated by 4–6 days.
s-SHBG, sex hormone binding globulin; s-AND, sex hormone binding androstenedione.
Signficant changes from baseline caused by BFR or HST (P < 0.05). No difference was found between HST and BFR.